Silexion Therapeutics Reports Q3 2026 Net Loss of $2.5 Million; Doses First SIL204 Patient
Silexion Therapeutics reported a third-quarter 2026 net loss of $2.5 million, compared with $3.3 million a year earlier, and ended September with $4.8 million in cash and cash equivalents. The company also reported a nine-month net loss of $8.8 million. During the quarter, it dosed the first patien…